Nuwellis earnings release, May 12, 2026

Nuwellis, Inc. (NUWE) · Form 8-K, Item 2.02 · Filed · SEC filing

Nuwellis, Inc. Announces First Quarter 2026 Financial Results

MINNEAPOLIS – May 12, 2026 – Nuwellis, Inc.

(Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the first quarter ended March 31, 2026.

First Quarter and Recent Highlights:

The first quarter marked an important step in Nuwellis’ transition from strategic reset to execution. The quarter demonstrated progress across the Company’s commercial, financial, and platform priorities, with stronger Aquadex performance, continued pediatric momentum, and further expansion of its broader cardiorenal strategy.

“Q1 showed that the strategic reset we made in 2025 is beginning to translate into a more focused and commercially disciplined company,” said John Erb, Chairman and

Chief Executive Officer of Nuwellis. “We are concentrating our resources around the areas where Nuwellis has clear clinical relevance, existing customer traction, and a differentiated path to growth, while maintaining the financial discipline required to execute. Aquadex gives us the foundation, pediatrics gives us a distinct growth category, and Rendiatech expands our ability to think more broadly across the cardiorenal continuum.”

First Quarter 2026 Financial Results

Revenue for the first quarter of 2026 was $2.4 million, compared to $1.9 million in the prior-year quarter, a 26% increase over the prior year period. Revenue growth in the first quarter was driven by continued expansion across all core categories, including Pediatric, Adult Heart Failure, and Critical Care, along with growth in both system placements and utilization of Aquadex therapy.

Gross margin for the first quarter of 2026 was 70.1%, a 14% increase to the prior-year quarter. The gross margin improvement reflects improved pricing and product mix and switching to contract manufacturing.

Operating expenses for the first quarter of 2026 were approximately $6.0 million, compared to approximately $4.1 million in the prior-year quarter. The increase is driven by increased sales headcount and compensation associated with increased sales.

Net loss attributable to common shareholders for the first quarter of 2026 was approximately $4.3 million.

On March 31, 2026, the Company had no debt and cash, cash equivalents, and restricted cash of approximately $2.2 million.

Webcast and Conference Call Information

The Company will host a conference call and webcast at 9:00 AM ET today to discuss its financial results and provide an update on the Company's performance.

To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com.

Alternatively, you may access the live conference call by dialing 1-800-274-8461 (U.S.) or 1-203-518-9814 (international) and using the conference ID: NUWEQ1. An audio archive of the webcast will be available following the call on the Investors page.

For more information, visit www.nuwellis.com.

About Nuwellis

Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions, with a focus on safety, precision, and scalability across patient populations. For more information, visit www.nuwellis.com.

Financial statements

Income Statement

Three months ended March 31 — (in thousands, except per share amounts and weighted average shares outstanding)

Three months ended March 31 – 2026Three months ended March 31 – 2025
Net sales2,4031,904
Cost of goods sold719837
Gross profit1,6841,067
Operating expenses:Selling, general and administrative4,5253,577
Operating expenses:Research and development1,524550
Operating expenses:Total operating expenses6,0494,127
Operating expenses:Loss from operations-4,365-3,060
Operating expenses:Other income17
Operating expenses:Change in fair value of warrant liabilities2640
Operating expenses:Loss before income taxes-4,338-3,013
Operating expenses:Income tax expense-1
Operating expenses:Net loss-4,338-3,014
Operating expenses:Deemed dividend attributable to Series J Convertible Preferred Stock21
Operating expenses:Net loss attributable to common shareholders-4,336-3,013
Operating expenses:Basic and diluted loss per share-2.09-28.98
Operating expenses:Weighted average shares outstanding – basic and diluted2,074,940104,142
Other comprehensive loss:Net loss-4,338-3,014
Other comprehensive loss:Foreign currency translation adjustments$--2
Other comprehensive loss:Total comprehensive loss-4,338-3,016

Balance Sheet

March 31, 2026 — (in thousands, except share and per share amounts)

March 31, 2026 – (Unaudited)December 31, 2025
Current assetsCash and cash equivalents2,0831,085
Current assetsAccounts receivable1,5591,493
Current assetsInventories, net1,7791,910
Current assetsOther current assets406698
Current assetsTotal current assets5,8275,186
Current assetsProperty, plant and equipment, net365368
Current assetsOperating lease right-of-use asset237293
Current assetsIntangible assets, net317
Current assetsOther assets420271
Current assetsTOTAL ASSETS7,1666,118
Current liabilitiesAccounts payable and accrued liabilities2,4292,226
Current liabilitiesAccrued compensation852460
Current liabilitiesCurrent portion of operating lease liability265261
Current liabilitiesDeferred consideration from Rendiatech acquisition, current113
Current liabilitiesOther current liabilities7185
Current liabilitiesTotal current liabilities3,7303,032
Current liabilitiesDeferred consideration from Rendiatech acquisition, non-current200
Current liabilitiesWarrant liabilities362389
Current liabilitiesOperating lease liability67
Current liabilitiesTotal liabilities4,2923,488
Commitments and contingenciesMezzanine Equity Series J Convertible Preferred Stock as of March 31, 2026 and December 31, 2025, par value $0.0001 per share; authorized 600,000 shares, issued and outstanding 147 and 137, respectively86
Stockholders’ equityAdditional paid‑in capital323,508318,928
Accumulated other comprehensive income:Foreign currency translation adjustment88
Accumulated other comprehensive income:Accumulated deficit-320,650-316,312
Accumulated other comprehensive income:Total stockholders’ equity2,8662,624
Accumulated other comprehensive income:TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY7,1666,118

Cash Flow

Three months ended March 31 — (in thousands)

Three months ended March 31 – 2026Three months ended March 31 – 2025
Operating Activities:Net loss-4,338-3,014
Adjustments to reconcile net loss to cash flows used in operating activities:Depreciation and amortization3873
Adjustments to reconcile net loss to cash flows used in operating activities:Stock-based compensation expense2567
Adjustments to reconcile net loss to cash flows used in operating activities:Change in fair value of warrant liabilities-26-40
Adjustments to reconcile net loss to cash flows used in operating activities:Non-cash IP R&D from Rendiatech acquisition552
Changes in operating assets and liabilities:Accounts receivable-66187
Changes in operating assets and liabilities:Inventory, net181-34
Changes in operating assets and liabilities:Other current assets29341
Changes in operating assets and liabilities:Other assets Other liabilities-17145
Changes in operating assets and liabilities:Accounts payable and accrued expenses400139
Changes in operating assets and liabilities:Net cash used in operating activities-3,112-2,536
Investing Activities:Purchases of property and equipment-30
Investing Activities:Purchase of intangible assets-90
Investing Activities:Cash paid for acquisition of Rendiatech, net of cash acquired-164
Investing Activities:Net cash used in investing activities-284
Financing Activities:Issuance of common stock and warrants from offering, net4,393
Financing Activities:Non-cash Series J deemed dividend2
Financing Activities:Net cash provided by financing activities4,395
Financing Activities:Effect of exchange rate changes on cash-2
Financing Activities:Net increase (decrease) in cash and cash equivalents999-2,538
Financing Activities:Cash and cash equivalents, and restricted cash - beginning of period1,1905,095
Financing Activities:Cash and cash equivalents, and restricted cash - end of period2,1892,557
Full release

Forward-Looking Statements

Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.

For further information, please contact:

NUWELLIS, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

NUWELLIS, INC. AND SUBSIDIARIES... (truncated)rations and Comprehensive Loss

(Unaudited)

(in thousands, except per share amounts and weighted average shares outstanding)

NUWELLIS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(in thousands)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Nuwellis earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.